Allogeneic Hematopoietic Cell Transplant

PROCEDURE2 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Medical College of Wisconsin

Conditions

Hematologic MalignanciesMDS

Phase 2

Phase II Trial of Pentostatin and Targeted Busulfan

CompletedNCT00496340

H. Lee Moffitt Cancer Center and Research InstituteHematologic Malignancies

Start: 2007-07-31End: 2013-08-31Updated: 2014-06-05

Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)

CompletedNCT02016781

Medical College of WisconsinMDS

Start: 2013-12-16End: 2021-10-05Updated: 2023-03-03

Related Papers

Out-of-Pocket Costs and Financial Hardship Among Participants of the BMT CTN 1102 Study

Blood2023-11-02

Health‐related quality of life in reduced‐intensity hematopoietic cell transplantation based on donor availability in patients aged 50–75 with advanced myelodysplastic syndrome: <scp>BMT CTN</scp> 1102

American Journal of Hematology2022-10-1719 citations

Health-Related Quality of Life in a Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome

Blood2021-11-05

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Blood2020-11-0515 citations